Novo Nordisk (NYSE: NVO) shares suffered their sharpest decline in months after the drugmaker’s long-term strategy failed to ease concerns about slowing growth, pricing pressure, and its reliance on semaglutide, even as fresh Phase 3 data gave investors a more favorable look at next-generation obesity candidate CagriSema.
Novo’s U.S.-listed shares closed 7.96% lower at $39.80 on Monday, Sept. 21, down from $43.24 in the previous session. Trading volume reached about 49.34 million shares, more than four times its roughly 12 million-share average, underscoring the intensity of the reaction.
The decline stood out against a strong day for the broader U.S. market. The S&P 500 advanced 1.49% Monday, while the Nasdaq Composite closed at a record high, suggesting the pressure on Novo was primarily company-specific rather than part of a broad risk-off move.
The selloff followed Novo’s Capital Markets Day in London, where management laid out its ambitions through 2030 but stopped short of providing the level of growth acceleration some investors had hoped for. A day later, CEO Mike Doustdar added another dimension to the developing story, saying Novo was prepared to look externally for drugs that could fill gaps in its pipeline or outperform medicines being developed internally.
Novo’s 2030 Targets Did Not Resolve the Semaglutide Question
Novo’s Capital Markets Day was intended to show how the company plans to sustain growth as competition intensifies and patent protection for semaglutide — the active ingredient in Wegovy and Ozempic — approaches expiration in major markets in the early 2030s.
Management set several longer-term strategic ambitions for 2030. Novo wants to launch more than five medicines capable of generating multibillion-dollar annual sales by 2030, enter or complete at least five Phase 3 programs in obesity and diabetes and at least five in other therapeutic areas by 2030, and serve more than 60 million patients globally by the end of the decade. The company also wants to build enough capacity to serve about 15 million patients with oral obesity therapies.
Novo also said it aims to deliver 2026–2030 revenue CAGR in line with industry peers while maintaining a broadly stable operating margin, with both ambitions based on adjusted metrics. The company stressed that these are strategic ambitions, not financial outlook or guidance.
The problem for the stock was less the absence of growth than the level of growth implied.
Reuters reported that BMO Capital Markets analyst Evan Seigerman interpreted Novo’s targets as pointing to roughly 3.6% annual revenue growth, a pace he said was already embedded in market expectations. Investors also questioned management about whether next-generation obesity medicines could maintain premium pricing after semaglutide loses exclusivity.
Those concerns are financially significant because Ozempic and Wegovy remain the core of Novo’s business. Reuters reported Tuesday that the two products account for about three-quarters of company sales. Competition is also intensifying, particularly from Eli Lilly, whose Zepbound franchise has gained ground against Wegovy.
Against that backdrop, Monday’s reaction suggested that ambitious pipeline targets alone were not enough to change investor expectations. Novo still needs to demonstrate that its next generation of products can replace enough of the growth and economics associated with semaglutide before the patent cliff becomes material.
CagriSema Data Improve the Pipeline Story — With an Important Dose Caveat
The investor-day weakness came despite encouraging new CagriSema results.
Novo said the REIMAGINE 5 Phase 3 trial tested once-weekly CagriSema at 1.0 mg of cagrilintide plus 1.0 mg of semaglutide against tirzepatide 5 mg in adults with type 2 diabetes inadequately controlled by existing therapy.
At week 60, patients receiving CagriSema lost an estimated 12.4% of body weight, compared with 9.1% for tirzepatide. CagriSema reduced HbA1c by 1.71 percentage points versus 1.67 points for tirzepatide, satisfying the non-inferiority objective for glycemic control.
Novo also reported results from the Phase 3 REDEFINE 9 obesity study. The 1.0 mg/1.0 mg dose of CagriSema produced 21.0% weight loss at 68 weeks, compared with 2.0% for placebo.
The findings add evidence that CagriSema can produce substantial weight loss at lower doses, but the tirzepatide comparison requires context. REIMAGINE 5 used the 5 mg tirzepatide dose rather than Lilly’s maximum 15 mg dose.
That distinction is particularly relevant because Novo’s earlier REDEFINE 4 head-to-head obesity study compared the higher 2.4 mg/2.4 mg dose of CagriSema with tirzepatide 15 mg. CagriSema produced 23.0% weight loss under the efficacy estimand versus 25.5% for tirzepatide, and the study failed its primary objective of demonstrating non-inferiority.
The new diabetes results therefore improve the evidence supporting CagriSema at lower doses, but they do not erase the earlier high-dose head-to-head result.
FDA Decision Could Turn CagriSema Into a Commercial Catalyst
Novo filed CagriSema with the U.S. Food and Drug Administration in December 2025 for chronic weight management. The application covers the 2.4 mg/2.4 mg fixed-dose combination of cagrilintide and semaglutide.
The company now expects an FDA decision in Q4 2026. If approved, Novo is targeting a launch in early 2027, potentially making CagriSema the first injectable treatment combining a GLP-1 receptor agonist with an amylin analogue.
The regulatory decision is important because it would move CagriSema from clinical development toward commercial execution at a time when Novo is trying to broaden its future growth base beyond its current semaglutide franchise.
Additional CagriSema development is already planned. The REDEFINE 11 Phase 3 study evaluating the full weight-loss potential of CagriSema 2.4 mg/2.4 mg is expected to report in the first half of 2027, while Novo has also planned development of a higher-dose combination.
Doustdar Opens the Door Wider to Acquisitions
Novo’s developing M&A strategy adds another potential route to rebuilding and expanding its pipeline.
Doustdar said Tuesday that Novo was willing to acquire outside assets when other companies have developed drugs that could fill gaps or perform better than Novo’s internal candidates.
“Let’s see where the gaps are, and let’s go out and see who has produced or is about to introduce better drugs than we can do on our own,” Doustdar told CNBC, according to a Reuters report.
The remarks reinforced comments from Monday’s investor meeting, where Novo said its balance sheet could support acquisitions larger than traditional bolt-on transactions. Importantly, the company said its target of more than DKK150 billion in 2035 pipeline sales is based on internal, risk-adjusted assets and does not include future M&A, meaning acquisitions could add to that target rather than simply help achieve it.
Doustdar indicated there may be greater acquisition opportunities in obesity-adjacent areas such as cardiovascular disease than in obesity itself. Such deals could broaden Novo’s pipeline while allowing the company to use its existing cardiometabolic commercial infrastructure.
NVOon Reflects the Equity Pressure in Tokenized Markets
Meanwhile, Novo’s selloff was also reflected in tokenized equity markets.
CoinMarketCap data showed Novo Nordisk Tokenized Stock (Ondo), or NVOon, at $40.55, down 4.81% over 24 hours, with about 52.36K tokens in circulation and a market capitalization of approximately $2.12 million.
NVOon is separate from the NYSE-listed ADR. Ondo Global Markets describes the instrument as a tokenized product designed to provide economic exposure similar to holding NVO, primarily for eligible non-U.S. users, and it can trade outside traditional U.S. exchange hours.
What Comes Next for Novo Nordisk Stock
Novo’s next scheduled corporate catalyst is its first-nine-month 2026 results on Nov. 4. Separately, the FDA is expected to decide on CagriSema in Q4 2026. Approval would shift attention from clinical evidence toward commercial execution, where pricing, access, demand, and competitive positioning against Lilly will become increasingly important.
Investors will also be able to compare Novo’s new long-range strategy against near-term sales trends for Wegovy and Ozempic, margins, guidance, and progress in oral obesity treatments.
Monday’s nearly 8% decline showed that the market remains focused on whether Novo can convert its pipeline ambitions into a growth profile strong enough to offset the eventual erosion of semaglutide exclusivity. CagriSema, the FDA decision, and a more open M&A strategy now form three of the clearest tests of that plan.
